博瑞医药筹划发行H股股票并在香港联交所上市

Core Viewpoint - The company, Borui Pharmaceutical, announced its plan to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its international strategy and enhance its overseas business layout [1] Group 1: Company Strategy - The company aims to strengthen its overseas financing capabilities and improve its capital strength and overall competitiveness through this H-share issuance [1] - The company will consider the interests of existing shareholders and the conditions of domestic and international capital markets when selecting the appropriate timing and issuance window for the listing [1]